Introduction
============

Aniridia (OMIM [106210](http://omim.org/entry/106210)) is a bilateral, panocular disorder characterized by the absence of the iris. It is usually accompanied by developmental defects of the cornea, lens, retina, optic nerve, and/or the anterior chamber angle \[[@r1]\]. Approximately two thirds of all cases are transmitted as an autosomal dominant trait among families. The remaining one third are sporadic, with no family history \[[@r1]-[@r3]\]. Mutations in *PAX6* (OMIM [607108](http://omim.org/entry/607108)) have been shown to be responsible for aniridia in most patients \[[@r4]-[@r10]\]. In rare cases, *PAX6* mutations may cause other ocular abnormalities, such as cataracts \[[@r11]\], Peters anomaly \[[@r12],[@r13]\], foveal dysplasia, microphthalmia, and optic nerve malformations \[[@r14],[@r15]\]. To date, at least 334 mutations in [PAX6](http://www.hgmd.cf.ac.uk) have been identified \[[@r16]\]. However, the absence of *PAX6* mutations in some cases of aniridia implies that mutations in additional genes cannot be excluded \[[@r6]-[@r10]\]. This possibility is supported by recent reports: 1) mutations in the forkhead box C1 gene (*FOXC1*, OMIM [601090](http://omim.org/entry/601090)) are associated with aniridia in two families \[[@r17],[@r18]\] and 2) aniridia in patients with preserved visual function are not related to *PAX6* mutations \[[@r19]\].

Understanding the mutation spectrum and frequency will not only provide biomarkers for clinical practice but will also represent a fundamental basis for identifying any additional causative genes. The spectrum and frequency of *PAX6* mutations in Chinese aniridia patients has not been well identified for the following reasons \[[@r20]-[@r27]\]: 1) most reports only involved a single or a limited number of families and 2) mutations were usually detected by cycle sequencing (detection of small variations), in which a larger deletion involving part or all of the gene could not be detected. Cycle sequencing combined with multiplex ligation-dependent probe amplification (MLPA) has been shown to effectively detect small mutations and large deletions in *PAX6* \[[@r10]\]. In this study, both cycle sequencing and MLPA were used to detect mutations in the *PAX6* gene of 33 Chinese probands with aniridia.

Methods
=======

Patients
--------

Thirty-three unrelated probands with aniridia participated in this study, including six families previously analyzed by sequencing \[[@r22]\] and 27 newly selected families. Patients suspected of having Peters anomaly or Rieger syndrome were excluded. All aniridia patients in this study were recruited from our Pediatric and Genetic Eye Clinic at the Eye Hospital of the Zhongshan Ophthalmic Center, Guangzhou, China. Written informed consent that complied with the tenets of the Declaration of Helsinki and following the Guidance of Sample Collection of Human Genetic Diseases (863-Plan) by China's Ministry of Public Health was obtained from each participant before the study. Genomic DNA was prepared from venous blood.

Detection of *PAX6* mutations
-----------------------------

Thirteen pairs of primers ([Table 1](#t1){ref-type="table"}) were used to amplify the 14 exons (3 noncoding exons and 11 coding exons) and their adjacent intronic sequences of *PAX6* (NCBI human genome build 37.2, [NC_000011.9](http://www.ncbi.nlm.nih.gov/genome?term=NC_000011.9) for gDNA, [NM_001604.4](http://www.ncbi.nlm.nih.gov/nuccore/NM_001604.4) for cDNA, and [NP_001595.2](http://www.ncbi.nlm.nih.gov/protein/NP_001595.2) for protein). The PCR products of individual exons for each patient were sequenced using the ABI BigDye Terminator v3.1 Cycle Sequencing Kit (ABI Applied Biosystems, Foster City, CA) and the ABI 3100 Genetic Analyzer (ABI Applied Biosystems) according to the manufacturer's recommendations. Sequencing results from patients' sequences and *PAX6* consensus sequences from the National Center for Biotechnology Information ([NCBI](http://www.ncbi.nlm.nih.gov/nuccore/NC_000011.9?from=31806340&to=31839509&report=genbank&strand=true)) human genome database ([NC_000011.9](http://www.ncbi.nlm.nih.gov/nuccore/NC_000011.9?from=31806340&to=31839509&report=genbank&strand=true)) were imported into the SeqManII program of the Lasergene package (DNAStar Inc., Madison, WI) and aligned to identify variations. Each mutation was confirmed by bidirectional sequencing. Mutation descriptions followed the nomenclature recommended by the Human Genomic Variation Society ([HGVS](http://www.hgvs.org/mutnomen/)) \[[@r28]\].

###### Primers used for amplification and sequencing of *PAX6*.

  **Primer ID**   **Sequence (5′-3′)**        **Product length (bp)**   **Annealing Temperature (°C)**
  --------------- --------------------------- ------------------------- --------------------------------
  Extra-E1-F\*    GAGCTGTGCCCAACTCTAGC                                   
  Extra E1-R      TCCATCTTTGTATGCCTCCTTT      399                       56
  Exon1F          GGAGAGGGAGCATCCAATC                                    
  Exon1R          TCCTGGGAAGGAGACAGAGA        396                       56
  Exon2F          ACACACTTGAGCCATCACCA                                   
  Exon2R          CTCCTGCGTGGAAACTTCTC        467                       56
  Exon3F          AGAGAGCCCATGGACGTATG                                   
  exon3R          CCCAATCTGTTTCCCCTACA        318                       56
  Exon4F          TGCAGCTGCCCGAGGATTA                                    
  Exon4R          GCACCCCGAGCCCGAAGTC         144                       66
  Exon5F          TCCCTCTTCTTCCTCTTCACT                                  
  Exon5R          GGGGTCCATAATTAGCATC         301                       61
  Exon6--7F\#     GCTCTCTACAGTAAGTTCTC                                   
  Exon6--7R       AGGAGAGAGCATTGGGCTTA        457                       61
  Exon8F          GATTTGCAGGTGTCATCAAT                                   
  Exon8R          ATATGGAGAGCTGCGTGGAT        212                       65
  Exon9F          TTTGGTGAGGCTGTCGGGA                                    
  Exon9R          TCTTTGTACTGAAGATGTGGC       339                       58
  Exon10F         GTAGTTCTGGCACAATATGG                                   
  Exon10R         GTACTCTGTACAAGCACCTC        206                       62
  Exon11--12F     GGCTCGACGTAGACACAGT                                    
  Exon11--12R     TGCAGACACAGCCAATGAGG        500                       62
  Exon13F         GCTGTGTGATGTGTTCCTCA                                   
  Exon13R         AAGAGAGATCGCCTCTGTG         245                       62
  Exon14F         CATGTCTGTTTCTCAAAGGG                                   
  Exon14R         CCATAGTCACTGACTGAATTAACAC   202                       61

^\#^Exon numbers are based on the current version of gene structure and [NM_001604.4](http://www.ncbi.nlm.nih.gov/nuccore/NM_001604.4), where the original exon 5a is numbered as exon 6. \*This extra exon is based on another transcript variant [NM_001127612.1](http://www.ncbi.nlm.nih.gov/nuccore/NM_001127612.1), which is not present in the trancript variant of [NM_001604.4](http://www.ncbi.nlm.nih.gov/nuccore/NM_001604.4).

MLPA analysis
-------------

For patients who were determined not to have a *PAX6* mutation based on sequencing analysis, MLPA was used to detect deletions of part or all of *PAX6*, according to the manufacturer's instructions (SALSA MLPA Kits P219-B1 *PAX6*; MRC-Holland bv, Amsterdam, the Netherlands) \[[@r10]\]. Briefly, 100 ng DNA samples were denatured for 5 min at 98 °C and then cooled to 25 °C. Probes were mixed and hybridized with DNA samples at 60 °C overnight and were then reacted with ligase 65 at 54 °C for 15 min, followed by 5 min at 98 °C and then held at 4 °C. Finally, all probes and sample ligations were amplified by PCR using specific carboxyfluorescein (FAM) labeled PCR primers. PCR products were separated by electrophoresis using the ABI PRISM 3100 Analyzer. Data analysis was performed using [GeneMarker](http://www.softgenetics.com/products.html) V1.5 software. A peak area between 0.7 and 1.3 times was considered normal; however, peak areas below 0.7 represent deletions and those above 1.3 represent duplications.

Results
=======

Sequencing of the 14 exons of *PAX6* of the 27 probands revealed 12 mutations in 13 patients, including five novel deletion/insertion mutations and seven known point mutations, as follows: c.\[65_94del30; 99_105dup7\] (p.P22LfsX25), c.101_102insA (p.Q34fsx21), c.177delG (R59SfsX19), c.238_239insGCGA (p.S80fsx12), c.1033--42_1033--26del17insG (splice change), c.1A\>G (Initiation codon abolished), c.120C\>A (p.C40X), c.718C\>T (p.R240X), c.949C\>T (p.R317X), c.1062C\>A (p.Y354X), c.1183G\>A (p.G395R), and c.1268A\>T (p.X423LeuextX\*15; [Table 2](#t2){ref-type="table"}, [Figure 1](#f1){ref-type="fig"} and [Figure 2](#f2){ref-type="fig"}). Of the 12 observed mutations, eight resulted in a premature stop codon. The other four were involved in the splicing acceptor, initial codon, or the stop codon. No putative mutations were detected in the other 14 probands. No variants were detected in the three noncoding exons (exons 1\~3).

###### Clinical data and *PAX6* mutations in the 16 probands.

  ID      Age (years)   Gender   Inheritance   Visual acuity   Clinical manifestation^\#^   Mutations detected in *PAX6*                                                                                  
  ------- ------------- -------- ------------- --------------- ---------------------------- ------------------------------ -------------------------------------- -------- ------------------------------ ----------------------------
  QT183   8             M        sporadic      0.1; 0.1        normal                       complete aniridia              inferior opacity; upward dislocation   E5       c.120C\>A                      C40X
  QT314   3/12          F        sporadic      NA              normal                       complete aniridia              transparent                            E9       c.718C\>T                      R240X
  QT322   12            M        AD            0.1; 0.1        normal                       subtotal aniridia              punctate opacity                       E5       c.65_94del30.c.99_105dup7      P22LfsX25
  QT346   3             M        sporadic      NA              inferior leucoma             complete aniridia              transparent                            E12      c.1183G\>A                     G395R
  QT350   4             M        sporadic      0.1; 0.1        normal                       complete aniridia              transparent                            E9--14   E9--14 del.                    One copy deletion
  QT374   7             M        sporadic      0.1; 0.1        normal                       complete aniridia              transparent                            E10      c.949C\>T                      R317X
  QT462   4             F        sporadic      NA              normal                       complete aniridia              transparent                            E8--14   E8--14 del.                    One copy deletion
  QT464   19            M        AD            0.2; 0.2        normal                       complete aniridia              punctate opacity                       E5       c.101_102insA                  p.H34QfsX21
  QT467   3             F        AD            NA              normal                       subtotal aniridia              punctate opacity                       E1--14   E1--14 del.                    One copy deletion
  QT468   8             M        AD            0.2; 0.2        normal                       circumpupillary aplasia        punctate opacity                       E6       c.238_239dupGCGA               T80Sfsx12
  QT517   2/12          M        sporadic      NA              normal                       complete aniridia              transparent                            E6       c.177delG                      R59SfsX19
  QT522   18            F        AD            0.1; 0.1        microcornea                  complete aniridia              punctate opacity                       E4       c.1A\>G                        Initiation codon abolished
  QT572   17            F        AD            0.2; 0.3        normal                       complete aniridia              punctate opacity                       E12      c.1033--42_1033--26del17insG   Splice change
  QT602   14            M        AD            0.1; 0.1        normal                       circumpupillary aplasia        transparent                            E12      c.1062C\>A                     Y354X
  QT609   5             F        AD            0.1; 0.2        normal                       complete aniridia              transparent                            E13      c.1268A\>T                     X423LeuextX\*15
  QT634   7             F        AD            0.1; 0.1        normal                       full iris\*                    punctate opacity                       E13      c.1268A\>T                     X423LeuextX\*15

Note: \# Nystagmus and foveal hypoplasia were present in all patients with PAX6 mutations. AD: Autosomal dominant. NA: Not available. \*Her father had the same mutation but had complete aniridia.

![Frameshift mutations detected in *PAX6*. Five novel deletion/insertion mutations were identified in five probands with aniridia from unrelated families. Pedigrees (left) are accompanied with sequence chromatography (right). Arrows indicate the probands. R represents reverse sequence.](mv-v17-2139-f1){#f1}

![Point mutations detected in *PAX6*. One missense and six nonsense mutations in PAX6 were found in eight probands with aniridia from unrelated families. From left to the right, the columns represent pedigrees, sequencing results from probands with aniridia, and corresponding sequences from normal controls.](mv-v17-2139-f2){#f2}

For the 20 probands in whom *PAX6* mutations were not detected by sequencing, including the remaining 14 probands from this study and six probands from our previous study \[[@r22]\], we detected *PAX6* deletions involving multiple exons (exons 1--14, 8--14, or 9--14, respectively) in three probands detected by MLPA ([Table 2](#t2){ref-type="table"}, [Figure 3](#f3){ref-type="fig"}).

![*PAX6* mutations detected by MLPA. Three gross deletions were involved in exons 9--14, 8--14, and 1--14, respectively. Black arrows indicate the exons with deletions, in which each peak area is below 0.7 compared to internal controls.](mv-v17-2139-f3){#f3}

Of the 16 probands with *PAX6* mutations, all had congenital nystagmus and foveal dysplasia. Complete aniridia, subtotal aniridia, circumpupillary aplasia, or a full iris in both eyes was recorded in probands 11, 2, 2, and 1, respectively ([Table 2](#t2){ref-type="table"}). One proband (QT634) had a full iris, but his father harbored the same heterozygous *PAX6* mutation and had complete aniridia. Additional ocular abnormalities included lens opacities (eight probands), inferior corneal leukoma (one proband with the missense mutation), and microcornea (one proband). The visual acuity of all probands ranged from 0.1 to 0.3, except for five children who were too young to be evaluated ([Table 2](#t2){ref-type="table"}). Phenotypic variations in the family harboring the c.1A\>G mutation were observed: one proband (QT522) had complete absence of the iris in both eyes, although her mother with the same *PAX6* mutation only had iris defects similar to iris coloboma ([Figure 4](#f4){ref-type="fig"}). The patient with the missense mutation (c.1183G\>A, p.G395R) had typical aniridia and inferior corneal leukoma.

![Photos showing the clinical phenotype of patients with a heterozygous c.1A\>G mutation in *PAX6*. **A** and **B**: Complete absence of iris and microcornea (9.5 mm in diameter) was observed in both eyes of the proband, an 18-year-old girl. **C** and **D**: A partial defect of the bilateral iris mimicking iris coloboma was present in the proband's mother, who also had the mutation. **E** and **F**: Foveal hypoplasia was observed in the mother (**E**) and the proband (**F**). **G** and **H**: A flat fovea (**G**) and optic disc hypoplasia (**H**) in the mother were demonstrated by optical coherence tomography and Heidelberg retinal tomography, respectively.](mv-v17-2139-f4){#f4}

Discussion
==========

The mutation frequency of *PAX6* in Chinese aniridia patients is similar to that in Caucasian aniridia patients. In this study, *PAX6* mutations were identified in 16 of the 33 families tested. When the results of this study are combined with those of our previous study \[[@r22]\], the *PAX6* mutations have been identified in 21 of 38 unrelated patients using cycle sequencing and MLPA. Of the 21 patients, mutations in 18 patients were identified by analyzing *PAX6* coding regions using direct sequencing, and mutations in 3 patients were detected using MLPA. For *PAX6* mutations in Chinese aniridia patients, the overall mutation detection rates detected with cycle sequencing, MLPA, or both were 47% (18/38), 8% (3/38), and 55% (21/38), respectively. In a similar study of Caucasian aniridia patients \[[@r10]\], *PAX6* mutations were detected in 49% (34/70), 11% (8/70), and 60% (42/70) patients with cycle sequencing, MLPA, or both, respectively. Several other studies have detected aniridia-associated *PAX6* mutations in 30% (9/30) of Mexican patients \[[@r29]\], 56% of Indian patients \[[@r30]\], 67% (4/6) of Thai patients \[[@r31]\], 38%--58% (3/8--14/24) of German patients \[[@r32],[@r33]\], 50% (2/4) of Japanese patients \[[@r34]\], 79% (30/38) of Danish patients \[[@r35]\], and 83%--94% (10/12--67/71) of British patients \[[@r9],[@r36]\]. The detection of these mutations was based solely on sequence analysis in most studies, but chromosomal analysis was additionally performed in a few studies. These reports demonstrate that while *PAX6* mutations were prevalent, they were not detected in all patients with aniridia. One reason that may account for this is the possibility that small variations outside the exons, such as intronic regions \[[@r10]\], may not be detectable by the techniques used to analyze *PAX6*. Furthermore, frequent chromosomal rearrangements have been described in aniridia patients previously \[[@r37]\], which may not be detectable by cycle sequencing and MLPA. It is also possible that there are mutations in other genes which contribute to aniridia given that mutations in *FOXC1* are associated with aniridia \[[@r17],[@r18]\] and that no *PAX6* mutations were detected in aniridia patients with preserved visual function \[[@r19]\].

The spectrum of *PAX6* mutations in aniridia is similar within both Chinese and Caucasian patient cohorts. The majority of *PAX6* mutations reported so far would lead to truncation of encoded proteins (such as nonsense, splicing, insertion, or deletion mutation) and only about 2%--11.7% are missense mutations \[[@r38],[@r39]\]. In one review \[[@r38]\], 257 aniridia-associated mutations were classified as nonsense mutations (38.9%), splice mutations (13.2%), frame-shifting insertions or deletions (25.3%), in-frame insertions or deletions (6.2%), missense mutations (11.7%), and run-on mutations (4.7%). For the 21 mutations in the Chinese patients analyzed in the present study, these percentages are 33.3%, 14.3%, 19.0%, zero, 9.5%, and 9.5%, with an additional 14.3% being gross deletions of the *PAX6* gene. In addition, seven point mutations detected in this study are known mutations, suggesting common mutations. Of the seven, the p.R240X and p.R317X mutations involving CpG dinucleotides are the most common nonsense mutations in *PAX6*. The p.C40X mutation was detected in one patient in this study and another patient in our previous study \[[@r22]\]. The run-on mutation, X423LeuextX\*15, was detected in two unrelated Chinese patients.

In this study, we detected five novel small insertion/deletion mutations, seven known point mutations, and three known gross deletions in 33 unrelated aniridia patients. In this and one of our previous studies \[[@r22]\], the *PAX6* gene was analyzed by cycle sequencing and MLPA in 38 unrelated aniridia patients. However, *PAX6* mutations were only detected in 55% (21/38) patients. Further studies of the 17 families without *PAX6* mutations may elucidate the molecular basis of aniridia in these families.
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